Study Evaluating the Efficacy and Safety of Selinexor (KPT-330) in Participants With Recurrent Gliomas

NCT01986348 · clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
76
Enrollment
INDUSTRY
Sponsor class

Stopped Study was terminated due to Sponsor decision (all except 1 patient were off-treatment and 2 patients were in survival follow-up)

Conditions

Interventions

Sponsor

Karyopharm Therapeutics Inc